Beta Bionics, Inc.
OperatingHealthcare · Irvine, CA
Financials
FY2014–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 4 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Cap table
Share counts as of Dec 31, 2022| Class | Outstanding | Votes / share | Share of total | Votes | Last price |
|---|---|---|---|---|---|
| Class A common stock | 5,890,000 | — | 99.8% | 100.0% | — |
| Class C Common Stock(as of Dec 31, 2021) | 9,691 | none | 0.16% | 0% | — |
| Total | 5,899,691 | 100% | 100% |
Shares outstanding over timein today's share terms
Principal holders% as the filing states it, Mar 28, 2025
- Entities affiliated with Eventide Asset Management4,857,041 Common Stock10.4%of company
- Zone Healthcare Holdings, LLC3,427,220 Common Stock7.4%of company
- Sands Capital Life Sciences Pulse Fund II, L.P.3,103,784 Common Stock6.7%of company
- Entities affiliated with RTW Investments3,099,191 Common Stock6.7%of company
- Wellington Hadley Harbor Aggregator IV, L.P.2,901,599 Common Stock6.2%of company
- Sean Saint802,558 Common Stock1.7%of company
- Adam Lezack2,674 Common Stock—of company
- Sean Carney75,515 Common Stock—of company
- Stephen Feider150,242 Common Stock—of company
- Maria Palasis, Ph.D.5,640 Common Stock—of company
- Christy Jones48,196 Common Stock—of company
- Mark Hopman63,310 Common Stock—of company
Sold to the crowd
- Reg CF · May 201650,761 shares at $19.70 in today's terms · sold as 10,000 shares at $100.00; since then a 10-for-1 split (Aug 2023), a 1-for-1.97 reverse split (Jan 2025)$1M
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
5 peopleNames and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 8 of 10 annual reports (FY2016–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 29 filings on EDGAR- Form 10-QJul 29, 20260001193125-26-323777EDGAR
- Form 10-QApr 21, 20260001193125-26-166843EDGAR
- Form 10-KFeb 24, 20260001193125-26-067065EDGAR
- Form 10-QOct 28, 20250001193125-25-253538EDGAR
- Form 10-QJul 29, 20250000950170-25-099652EDGAR
- Form 10-QMay 6, 20250000950170-25-064504EDGAR
- Form 10-K/AMar 28, 20250000950170-25-046762EDGAR
- Form 10-KMar 25, 20250000950170-25-044516EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.